Background: Primary bone marrow lymphoma (PBML) is a very uncommon neoplasm originally arising in the bone marrow system, and the most common pathological type is diffuse large B-cell lymphoma.
Background
Primary bone marrow lymphoma (PBML) is an extremely rare form of lymphoma with rapid disease progression and a poor prognosis.
1,2 A previous case series study conducted by Martinez et al 1 focused on the pathological features of PBML; however, only a few clinical features were found to be associated with the disease. Five different pathological types of lymphoma can originate in the bone marrow, including Hodgkin's lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma, not otherwise specified lymphoma (PTCL, NOS), ALK-negative anaplastic large cell lymphoma (ALK-negative ALCL), and follicular lymphoma (FL). 1 Among these types, DLBCL is the most common pathological subtype. However, due to the low incidence of the disease, large-scale and systematic case series studies are lacking; therefore, information regarding the clinical features of PBML is lacking. Additionally, the current treatments for PBML are not uniform and have not been standardized, and most treatments focus on only the pathological type and lack specificity and scientific evidence. Furthermore, no study has reported the risk factors affecting the outcomes of PBML. Thus, we reviewed some cases that had been diagnosed at our single center and analyzed previous studies. The present study aimed to investigate the specific clinical 1 In addition to the above mentioned diagnostic criteria, we added the following exclusion criteria: 1) cases with a second tumor or a disease that could seriously influence survival and 2) B-cell lymphomas that could not be further diagnosed.
All patients' clinical data, including sex, age, initial symptoms, peripheral blood indicators at first admission, LDH level, β-2 microglobulin level, international prognostic index, treatment modality, treatment response, and radiological findings, were collected. The bone marrow examination included a bone marrow smear cytologic examination, bone marrow biopsy, and bone marrow aspiration.
This study was approved by the ethics committee of the First Affiliated Hospital of Zhengzhou University and was conducted in accordance with the Declaration of Helsinki. Written informed consent for the collection of medical information was obtained from all patients. All procedures performed in the study were in accordance with the ethical standards of the institutional research committee.
statistical analysis
Complete response (CR), partial response (PR), stable disease (SD), and progressive disease were used to define the classification of the treatment response according to the criteria for malignant lymphoma. The overall survival (OS) was defined from the date of pathological diagnosis to death or to the last date of follow-up. We divided the degree of cytopenia into the following four levels: Grade 0: leukocytes ≥4.0×10 9 /L, hemoglobin ≥110 g/L, platelets ≥100×10 9 /L; Grade 1: leukocytes (3. 
9 /L. OS and survival curves were analyzed by the Kaplan-Meier method. The survival of patients with different prognostic variables was analyzed by the log-rank test, and multiple independent prognostic factors were analyzed using a Cox proportional hazards regression analysis. The correlations between two variables were analyzed by Pearson's chi-square analysis. P-values <0.05 were considered statistically significant, and the statistical analyses were performed using SPSS 21.0.
Results

Patient characteristics in our center
Seven patients with PBML who were treated at the Lymphoma Diagnosis and Treatment Center of Henan Province were enrolled between July 2011 and June 2017 into this study; their clinical characteristics are listed in Table 1 . The median follow-up time was 10.4 months (range: 1.0-25 months) and the median age at diagnosis was 56 years (range: 38-72 years). There were five deaths, accounting for 71.4%. Of these patients, three patients died from treatment failure and other two patients finally succumbed to recurrence of the disease. Notably, PET/CT was used in four cases, and all cases revealed disseminated bone marrow with diffuse hypermetabolism, and the median standard uptake value level was 5.9 (range: 4.8-7.5).
literature review and statistical analysis
Data of 66 cases of PBML were collected and analyzed as follows: 7 cases were among the cases at our center and 59 cases were identified through searching PubMed, China National Knowledge Infrastructure, and Wanfang Data from 1997 to 2018, and the specific information of these patients is presented in Table 2 . Nineteen of them were excluded due to lack of specific follow-up time; finally, 47 cases were enrolled into this retrospective analysis. As shown in Table 2 , the female/male ratio of the patients was 4:7 (24:42), and the age ranged between 29 and 81 years (median: 60.0 years; average: 57.6 years). PBML occurred in various pathological types of lymphoma. The most common PBMLs were DLBCLs with 40 cases (60.6%). The other types included HL Abbreviations: all, prednisone, vincristine, daunorubicin, l-asparaginase, cyclophosphamide, cytarabine, bleomycin, 6-mercaptopurine; alK-negative alCl, alK-negative anaplastic large cell lymphoma; B, B symptoms; B2Mg, between the two variables. Considering the P-value of the univariable analysis and clinical convenience, we excluded the variable of degree of cytopenia from the Cox regression model. Finally, the LDH level, B symptoms, serum platelet level, and response to initial therapy were included in the Cox regression analysis, and a low serum platelet level, B symptom, and not achieving CR following the initial therapy showed an independent association with an unfavorable OS ( Table 5 ). In addition, because of the uniformity of the treatment options for DLBCL, we divided the patients into two groups: one group included 23 cases with RCHOP, RCHOP-like/CHOP, or CHOP-like regimens and the other group included 5 cases with intensive regimens, including HVPERCAVD, EPOCH, ALL, HD-CHOP, and VACOPB. The patients who had received intensive regimens showed a better OS (P=0.01; Figure 2 ). 
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Discussion
The present study is the largest study concerning PBML to date. To the best of our knowledge, regarding the clinical features and prognosis of primary marrow bone lymphoma, we are the first to perform a systematic and comprehensive review and establish a prognostic model of PBML. PBML has been sporadically reported in the literature since the 1970s. Compared with other lymphomas of the same pathological type, PBML is usually difficult to diagnose, progresses rapidly, and is easy to combine with multiple complications, such as severe infection and HLH, only part of people in the conventional treatment respond well, and OS is relatively short. [1] [2] [3] In some cases, a clear diagnosis lacks complete evidence, and often, primary bone lymphoma (PBL) cases, which occur infrequently, are misdiagnosed as PBMLs. Most clinical manifestations of PBLs include bone pain and fractures; most of the common lesion features are destructive through localized radiological examination; and the disease often presents with a local single lesion. 1, 4 In contrast to PBL, the important symptoms of PBML include cytopenia and B symptoms, and the occurrence of bone pain is relatively rare based on our data. Additionally, in our study, the lesion was usually confined to the marrow cavity during the early stage, and the PET/CT results of 13 patients, not only from our center but also from the literature review, all presented diffuse abnormal fluorodeoxyglucose uptake in the bone marrow that appeared to be more intense in the axial bones; therefore, we believe that PET/CT has a certain importance in the diagnosis of PBML, and so, we added this item to the criteria proposed by Martinez et al 1 in 2012. In addition, MRI usually reveals a diffusely abnormal marrow signal (low on T1-weighted images, high on T2-weighted images) in the bone marrow cavity. 5 Thus, imaging data can provide important information for the identification of PBL and PBML.
In our studies, three clinical variables were proved to be independent prognostic factors, including B symptoms, serum platelet levels, and response to initial treatment. In several studies about lymphoma, B symptoms have been found to be an important prognostic variable for OS. [6] [7] [8] The degree of cytopenia is clearly closely related to disease severity. 
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Wang et al Therefore, cytopenia likely affects prognosis. However, our results indicate that platelet count was also an independent factor affecting prognosis. In fact, based on our data, thrombocytopenia does not affect treatment or increase the number of bleeding events. Some early studies [9] [10] [11] have revealed that thrombocytopenia affects the survival results in lymphomas with bone marrow involvement, including PBML. In addition, a similar prognostic result was reported in early-stage B-cell gastric lymphoma 12 and DLBCL. 13, 14 We believe that autoimmune thrombocytopenia-associated PBML may be a potential cause because autoimmune-induced thrombocytopenia predicted relapse in one-third of lymphoma patients in a study. 15 Age, which is a classic risk factor, was no longer associated with the OS in our study. In some conventional studies, older age-associated poor prognosis may be caused by the following three potential factors: multiple comorbidity, lower tolerance to therapy, and multiple organ dysfunction, including bone marrow function. 16, 17 However, our study indicated that the incidence of complications was nearly equal between the older age group and the younger age group. Additionally, PBML is a disease that severely influences and impairs various organ functions, especially bone marrow function, thereby reducing chemotherapy tolerance. Thus, age seems to be less important than disease malignancy.
Compared with the data from literature review, the incidence of T-cell lymphoma in our center is relatively higher, and the data showed that OS seems to be shorter, which may be associated with a higher rate of B symptoms and HLH. Lymphoma-associated HLH is a relatively vicious disease associated with the uncontrolled activation of the normal immune system, 18, 19 and another important reason is that only two people achieved CR after initial treatment.
Patients with leukopenia or thrombocytopenia were all administered granulocyte-colony stimulating factor (G-CSF) or recombinant human thrombopoietin, but without success. Hammerstrøm reported that three patients with neutropenia secondary to lymphoid bone marrow involvement responded well to G-CSF before chemotherapy. 20 However, we found no other literature confirming this problem. Based on our single-center experience, G-CSF or recombinant human thrombopoietin treatment for cytopenia involving or originating in the bone marrow is usually ineffective.
Most patients with HL were treated with ABVD or an ABVD-like regimen. Unfortunately, more than half of these patients died in the short term, and disease progression was the dominant cause of death. Morita et al 21 reported that HIV-negative cases tended to progress rapidly and resulted in worse outcomes, which is consistent with our analysis.
Regarding T-cell lymphoma, we first used the gemcitabine, cisplatin, prednisone, and thalidomide regimen in our patients because this regimen was proven to be more efficient than CHOP for the treatment of PTCL in a prospective, randomized, controlled, and open-label clinical trial; 22 however, the results were not satisfactory and the results of the CHOP regimen were also not satisfactory. Some reports had mentioned that lymphomas, especially T-cell lymphomas, were the main cause of secondary HLH and were associated with a poorer prognosis. 23, 24 This condition also appeared in PBML. Among the patients with primary bone marrow T-cell lymphomas, two out of seven (28.6%) patients had HLH complications and died within a month. The clinical use of decitabine in T-cell PBML is a ground-breaking initiative, and the result that patients had increased long-term survival is also promising. Among all PBML cases, the FL cases seemed to show the mildest symptoms and best prognosis, likely due to the slow development of the disease itself. Martinez et al reported a patient who had leukocytosis as the only abnormal indicator at the time of onset and survived for >5 years until the end of follow-up. In the past two decades, most reported PBMLs have been DLBCLs. Regarding treatment, CHOP or the CHOP-like regimen was usually used as the first-line regimen, and only a small subset of patients (two cases) died from chemotherapy-related side effects during the initial therapy; our results showed that intensive regimens seem to be more effective. We suggest that this effectiveness might be because continuous low concentrations of drugs increased the effectiveness of killing aggressive cancer cells and decreased MDR-1-mediated resistance. [25] [26] [27] [28] Additionally, in some studies investigating aggressive non-Hodgkin's lymphoma with high-risk factors, the patients who received intensive chemotherapies actually showed a better OS than those treated with CHOP. 29, 30 In addition, some studies have published the following results in non-Hodgkin's lymphoma with bone marrow infiltration: the response rate, OS, and progression-free survival of patients treated with intensive regimens were significantly higher than those of patients treated with the standard CHOP regimen. 11, 31 In conclusion, we believe that intensive therapy may indeed be conducive to survival in PBML. However, another problem that cannot be ignored is that intensive treatment may lead to greater risks in PBML than other high-risk non-Hodgkin lymphomas. Thus, safety and chemotherapy tolerance require extensive data, and the CHOP or CHOP-like regimen remains a relatively safe and moderate regimen. Kazama et al 32 reported that a patient who underwent autologous stem cell transplantation (Auto-SCT) after eight cycles of RCHOP survived for >7 years, representing another clinically significant therapeutic initiative illustrating the possibility that Auto-SCT can improve prognosis. Five cases (case 35, case 39, case 55, case 57, and case 59) developed central nervous system involvement during follow-up, and case 59 developed neurological lesions despite intrathecal prophylaxis, indicating not only that intrathecal treatment is necessary, but also that more valuable therapeutic measures need to be investigated to prevent intracranial progression.
This study had some limitations. First, although we expanded the sample size by reviewing the literature, this study was still a relatively small-scale study, which might have influenced the accuracy of our results. Second, some data were missing in this retrospective study. Third, this study involved less discussion and analysis of target molecules, pathology, and biology.
Conclusion
PBML is a type of lymphoma with a relatively poor prognosis compared to other lymphomas. Patients usually have poor general condition at the time of onset and a poor tolerance to initial chemotherapy during the acute phase. The survival period is generally short. B symptoms, a low serum platelet level (<75×10 9 /L), and not achieving CR following initial therapy are unfavorable prognosis factors. Additionally, some intensive regimens that differ from traditional regimens or Auto-SCT are worth considering and further exploring. Furthermore, additional and larger prospective multicenter studies are required in the future.
